Cytotoxic agents comprising new maytansinoids

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8841425
APP PUB NO 20110158991A1
SERIAL NO

13043879

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

New thiol and disulfide-containing maytansinoids bearing a mono or di-alkyl substitution on the α-carbon atom bearing the sulfur atom are disclosed. Also disclosed are methods for the synthesis of these new maytansinoids and methods for the linkage of these new maytansinoids to cell-binding agents. The maytansinoid-cell-binding agent conjugates are useful as therapeutic agents, which are delivered specifically to target cells and are cytotoxic. These conjugates display vastly improved therapeutic efficacy in animal tumor models compared to the previously described agents.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
IMMUNOGEN, INC.WALTHAM, MA118

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Chari, Ravi V J Newton, US 79 1413
Widdison, Wayne C Somerville, US 24 294

Cited Art Landscape

Patent Info (Count) # Cites Year
 
IMMUNOGEN, INC. (17)
5208020 Cytotoxic agents comprising maytansinoids and their therapeutic use 232 1992
5416064 Cytotoxic agents comprising maytansinoids and their therapeutic use 156 1992
6333410 Process for the preparation and purification of thiol-containing maytansinoids 95 2000
2002/0001,587 Methods of treatment using anti-ErbB antibody-maytansinoid conjugates 45 2001
6441163 Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents 103 2001
6716821 Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same 81 2001
7374762 Drug conjugate composition 16 2004
* 2004/0241,174 Drug conjugate composition 19 2004
* 7276497 Cytotoxic agents comprising new maytansinoids 44 2004
7301019 Method for the preparation of maytansinoid esters 9 2006
7494649 Drug conjugate composition 13 2006
7501120 Drug conjugate composition 13 2006
7514080 Drug conjugate composition 14 2006
* 8435528 Cytotoxic agents comprising new maytansinoids 2 2007
* 8198417 Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates 15 2007
8012485 Drug conjugate composition 5 2009
2011/0300,162 DRUG CONJUGATE COMPOSITION 2 2011
 
The United States of America as represented by the Secretary of Agriculture (1)
4315929 Method of controlling the European corn borer with trewiasine 83 1981
 
SMITHKLINE BEECHAM P.L.C. (2)
6573074 Methods for ansamitocin production 8 2001
2003/0157,669 Ansamitocins 5 2003
 
GLAXOSMITHKLINE LLC (2)
6570024 Process and intermediates 8 2001
6884874 Process and intermediates 7 2003
 
ASTRAZENECA AB (1)
2005/0176,780 2,5-disubstituted 3-mercaptopentanoic acid 1 2004
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

  • No Forward Cites to Display

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Mar 23, 2018
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 23, 2022
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 23, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00